Radicava (edaravone)

Radicava (edaravone) is covered only for the FDA‑approved treatment of ALS and is not covered for non‑ALS indications. Coverage requires ALL initial criteria: definite/probable ALS by El Escorial/Airlie House, ALSFRS‑R ≥2 on every item, percent‑predicted FVC ≥80%, diagnosis ≤2 years, prior/current riluzole, and prescription/consultation by an ALS specialist; reauthorization is every 6 months with documented continued benefit, no invasive ventilation, continued specialist involvement, and dosing per the FDA label.

"Radicava is indicated for the treatment of amyotrophic lateral sclerosis (ALS)."

Sign up to see full coverage criteria, indications, and limitations.